Cerebral haemostasis and antiphospholipid antibodies

Lupus

Volumn 12, Issue 12, 2003, Pages 929-934

  Connor, P ^a   Hunt, B J ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid; Cerebral; Endothelium; Haemostasis

Indexed keywords

BLOOD CLOTTING INHIBITOR; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; BRAIN CIRCULATION; CELL ACTIVATION; ENDOTHELIUM CELL; GENE EXPRESSION; HEMOSTASIS; HUMAN; HUMAN TISSUE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CELLS, CULTURED; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; RISK ASSESSMENT; THROMBOSIS;

EID: 0345862377     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu504oa     Document Type: Review

References (51)

1. Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian registry. Am J Med 1996; 100: 530-536.
2. Comp PC, Elrod JP, Karzenski S. Warfarin induced skin necrosis. Semin Thromb Hemostat 1990; 16: 293-298.
3. Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986; 67: 362-365.
4. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 1983; 287: 1088-1089.
5. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antphospholipid antibody syndrome. N Eng J Med 1995; 332: 993-997.
6. Levine SR, Brey RL. Neurological aspects of antiphospholipid syndrome. Lupus 1996; 5: 409-413.
7. Herranz MT, Rivier G, Khamashta MA et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythromatosis. Arthritis Rheum 1994; 374: 568-571.
8. Denberg SD, Cabotte RM, Ginsberg JS, Denberg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with SLE. Int J Neuropsychol Soc 1997; 4: 377-386.
9. Willms-Kretschmer K, Flax MH, Cotran RS. The fine structure of the vascular response in hapten-specific delayed hypersensitivity and contact dermatitis. Lab Invest 1967; 17: 334-349.
10. Hunt BJ, Jurd KM. Endothelial cell activation. Brit Med J 1998; 316: 1328-1329.
11. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischaemic cerebrovascular disease. Stroke 2002; 33: 2115-2122.
12. Simantov R, LaSala JM, Lo SK, Gharavi A, Sammaritano LR, Salmon JE. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-2219.
13. Del Papa N, Guidali L, Sala A et al. Endothelial cells as targets for antiphospholipid antibodies. Arthritis Rheum 1997; 38: 212-217.
14. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997-2002.
15. Blank M, Shoenfield Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by peptides. Proc Natl Acad Sci USA 1999; 96: 5164-5168.
16. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 1444-1456.
17. 2-glycoprotein I to human atherosclerotic plaques. Circulation 1999; 99: 2227-2230.
18. Shoenfeld GJ, Harats D. The involvement of beta2-glycoprotein I in human and murine atherosclerosis. J Autoimmun 1999; 13: 57-60.
19. 2 glycoprotein I. Circulation 1998; 15: 1108-1115.
20. Cervera R, Khamashta MA, Font J et al. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity 1991; 11: 1-6.
21. Hill MB, Phipps JL, Malia RG, Greaves M, Hughes P. Characterisation and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in the primary antiphospholipid syndrome. Clin Exp Immunol 1995; 102: 368-372.
22. Williams MK, Parmar K, Hughes GRV, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000; 84: 742-746.
23. Nagy Z. Blood-brain barrier and the cerebral endothelium. In Johanasson BB, Owman C, Kan Widner H eds. Pathophysiology of the blood-brain barrier, Amsterdam: Elsevier Science Pub, 1990; 11-29.
24. Rosenbreg R, Aird W, Vascular bed specific hemostasis and hypercoagulable states. N Eng J Med 1999; 340: 1555-1564.
25. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thrombo-embolic disease: a clinical perspective. Ann Intern Med 1997; 127: 895-803.
26. Dilwari JB, Bambery P, Chawala Y et al. Hepatic outflow obstruction (Budd-Chiari syndrome): experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994; 73: 21-36.
27. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural History of Paroxysmal nocturnal haemoglobinuria. N Eng J Med 1995; 333: 1253-1258.
28. Socie G, Mary JY, de Gramont A et al. Paroxysmal nocturnal haemoglobinuria: long term follow-up and prognostic factors. Lancet 1996; 348: 573-577.
29. Weiler-Guettler H, Christie PD, Beeler DL et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998; 101: 1983-1991.
30. Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Ukitsu M. Local variation in the expression of pro- and antithrombotic factors in vascular endothelium of human autopsy brain. Acta Neuropathol 1999; 98: 111-118.
31. Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Transcription expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82: 1047-1052.
32. Jacobsen EM, Ssandset PM, Wisloff F. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor? Thromb Res 1999; 94: 213-220.
33. Amengual O, Atsumi T, Khamshta MA, Hughes GR. The role of tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-281.
34. Thomas WS, Mori E, Copeland BR, Yu JQ, Morissey JH, Del Zoppo GJ. Tissue factor contributes to microvascular defects after focal cerebral ischaemia. Stroke 1993; 24: 847-854.
35. Van Nostrand WE, Schmaier AH, Farrow JS, Cunningha, DD. Protease nexin-ii (amyloid β-protein precursor): a platelet alpha-granule protein. Science 1990; 248: 745-748.
36. Van Nostrand WE, Wagner SL, Farrow JS, Cunningham DD. Immunopurification and protease inhibitory properties of protease nexin-2/amyloid β-protein precursor. J Biol Chem 1990; 265: 9591-9594.
37. Sandbrink R, Masters CL, Beyreuther K. APP gene family: alternative splicing generates functionally related isoforms. Ann Acad Sci 1996; 777: 281-287.
38. Smith RP, Higuchi DA, Broze GJ. Platelet coagulation factor Xia-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248: 1126-1128.
39. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
40. Cuzner ML, Gveric D, Strand C et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in evolution. J Neuropathol Exp Neurol 1996; 55: 1194-1204.
41. Levin EG, Santell L, Osborn KG. The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomical location. J Cell Sci 1997; 110: 139-148.
42. Rand JH, Badimon L, Gordon RE et al. Distribution of von Willebrand factor in porcine intima varies with blood vessel type and location. Arteriosclerosis 1987; 7: 47-54.
43. Bahnak BR, Wu QY, Coulombel L et al. Expression of von Willebrand factor in porcine vessels: Heterogeneity at the level of von Willebrand mRNA. J Cell Physiol 1989; 138: 305-310.
44. Shyy YJ, Li YS, Lin MC et al. Multiple cis-elements mediate shear stress-induced gene expression. J Biomech 1995; 28: 1451-1457.
45. Lin MC, Almus-Jacobs F, Chen HH et al. Shear stress induction of the tissue factor gene. J Clin Invest 1997; 99: 737-744.
46. Marsden PA, Heng HH, Scherer SW et al. Stucture and chromosomal localisation of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-17488.
47. Resnik N, Collins T, Atkinson W et al. Platelet-derived growth factor B chain promotor contains a cis-acting fluid shear stress responsive element. Proc Natl Acad Sci USA 1993; 88: 4591-4595.
48. Fukuchi M, Watanabe J, Kumagai, Katori Y. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Col Cardiol 2001; 37: 1436-1442.
49. Del Zoppo G, Yu JQ, Copeland BR, Thomas WS, Schneiderman J, Morrissey J. Tissue factor localisation in non-human primate cerebral tissue. Thromb Haemost 1992; 68: 642-647.
50. Drake TA, Morrissey J, Edington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of thrombosis and haemostasis. Am J Pathol 1989; 134: 1087-1097.
51. Kallmann BA, Wagner S, Hummel V et al. Characteristic gene expression profile of primary human cerebral endothelial cells. FASEB J 2002; 16: 589-591.